  Generally speaking, a successful party - in this case Apotex - is entitled to its costs. According to Rule 407 of the Rules, these costs are typically assessed at the mid-point of Column III of Tariff B, along with certain additional fees and disbursements. However, numerous judgments stemming from pharmaceutical patent cases have determined that costs are to be assessed at the upper end of Column IV of Tariff B, given the complexity of the issues raised by such cases